METHODS AND COMPOSITIONS INVOLVING SLC17A1

摘要

The present invention concerns methods and compositions for evaluating whether an EGFR-targeted agent is a promising treatment option in a patient based on the level of expression of a gene called SLC17Al . It was determined that cells sensitive to SLC17Al had a significantly greater amount of gene expression of SLC17A1 than cells considered resistant to SLC17A1. Other aspects of the invention include methods for identifying other such candidate markers for drug toxicity and/or drug efficacy.